Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.

Dharma Rao T, Park KJ, Smith-Jones P, Iasonos A, Linkov I, Soslow RA, Spriggs DR.

Appl Immunohistochem Mol Morphol. 2010 Oct;18(5):462-72. doi: 10.1097/PAI.0b013e3181dbfcd2.

2.

Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.

Rao TD, Tian H, Ma X, Yan X, Thapi S, Schultz N, Rosales N, Monette S, Wang A, Hyman DM, Levine DA, Solit D, Spriggs DR.

PLoS One. 2015 May 12;10(5):e0126633. doi: 10.1371/journal.pone.0126633. eCollection 2015.

3.

MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope.

Argüeso P, Spurr-Michaud S, Russo CL, Tisdale A, Gipson IK.

Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2487-95.

PMID:
12766047
4.

Characterization of binding epitopes of CA125 monoclonal antibodies.

Marcos-Silva L, Narimatsu Y, Halim A, Campos D, Yang Z, Tarp MA, Pereira PJ, Mandel U, Bennett EP, Vakhrushev SY, Levery SB, David L, Clausen H.

J Proteome Res. 2014 Jul 3;13(7):3349-59. doi: 10.1021/pr500215g. Epub 2014 Jun 4.

PMID:
24850311
5.

Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene.

Yin BW, Dnistrian A, Lloyd KO.

Int J Cancer. 2002 Apr 10;98(5):737-40.

6.

MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells.

Lakshmanan I, Ponnusamy MP, Das S, Chakraborty S, Haridas D, Mukhopadhyay P, Lele SM, Batra SK.

Oncogene. 2012 Feb 16;31(7):805-17. doi: 10.1038/onc.2011.297. Epub 2011 Jul 25.

7.

MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.

Felder M, Kapur A, Gonzalez-Bosquet J, Horibata S, Heintz J, Albrecht R, Fass L, Kaur J, Hu K, Shojaei H, Whelan RJ, Patankar MS.

Mol Cancer. 2014 May 29;13:129. doi: 10.1186/1476-4598-13-129. Review.

8.

MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse.

Wang Y, Cheon DJ, Lu Z, Cunningham SL, Chen CM, Luo RZ, Xing D, Orsulic S, Bast RC Jr, Behringer RR.

Differentiation. 2008 Dec;76(10):1081-92. doi: 10.1111/j.1432-0436.2008.00295.x. Epub 2008 Jul 2.

9.

A binding domain on mesothelin for CA125/MUC16.

Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, Ho M.

J Biol Chem. 2009 Feb 6;284(6):3739-49. doi: 10.1074/jbc.M806776200. Epub 2008 Dec 15.

10.

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.

Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS.

Mol Cancer. 2006 Oct 26;5(1):50.

11.

A novel monoclonal antibody to a defined peptide epitope in MUC16.

Marcos-Silva L, Ricardo S, Chen K, Blixt O, Arigi E, Pereira D, Høgdall E, Mandel U, Bennett EP, Vakhrushev SY, David L, Clausen H.

Glycobiology. 2015 Nov;25(11):1172-82. doi: 10.1093/glycob/cwv056. Epub 2015 Jul 22.

PMID:
26201951
12.

Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation.

Chen SH, Hung WC, Wang P, Paul C, Konstantopoulos K.

Sci Rep. 2013;3:1870. doi: 10.1038/srep01870.

13.

Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying Golgi/post-Golgi compartments.

Das S, Majhi PD, Al-Mugotir MH, Rachagani S, Sorgen P, Batra SK.

Sci Rep. 2015 Jun 5;5:9759. doi: 10.1038/srep09759.

14.

Pathobiological implications of MUC16 expression in pancreatic cancer.

Haridas D, Chakraborty S, Ponnusamy MP, Lakshmanan I, Rachagani S, Cruz E, Kumar S, Das S, Lele SM, Anderson JM, Wittel UA, Hollingsworth MA, Batra SK.

PLoS One. 2011;6(10):e26839. doi: 10.1371/journal.pone.0026839. Epub 2011 Oct 31.

15.

Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents.

Rao TD, Rosales N, Spriggs DR.

Mol Cancer Ther. 2011 Oct;10(10):1939-48. doi: 10.1158/1535-7163.MCT-11-0228. Epub 2011 Aug 4.

16.

CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.

Boivin M, Lane D, Piché A, Rancourt C.

Gynecol Oncol. 2009 Dec;115(3):407-13. doi: 10.1016/j.ygyno.2009.08.007. Epub 2009 Sep 10.

PMID:
19747716
17.

Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy.

Das S, Batra SK.

Cancer Res. 2015 Nov 15;75(22):4669-74. doi: 10.1158/0008-5472.CAN-15-1050. Epub 2015 Nov 2. Review.

18.

MUC16: molecular analysis and its functional implications in benign and malignant conditions.

Haridas D, Ponnusamy MP, Chugh S, Lakshmanan I, Seshacharyulu P, Batra SK.

FASEB J. 2014 Oct;28(10):4183-99. doi: 10.1096/fj.14-257352. Epub 2014 Jul 2. Review.

19.

CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells.

Reinartz S, Failer S, Schuell T, Wagner U.

Eur J Cancer. 2012 Jul;48(10):1558-69. doi: 10.1016/j.ejca.2011.07.004. Epub 2011 Aug 16.

PMID:
21852110
20.

Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer.

Akita K, Yoshida S, Ikehara Y, Shirakawa S, Toda M, Inoue M, Kitawaki J, Nakanishi H, Narimatsu H, Nakada H.

Int J Gynecol Cancer. 2012 May;22(4):531-8. doi: 10.1097/IGC.0b013e3182473292.

PMID:
22367369

Supplemental Content

Support Center